Loading…
Glass House Brands Inc.
Glass House Brands Inc. (GLAS) is listed on NYSE and classified in Drug Manufacturers - Specialty & Generic, part of the Healthcare sector. It is headquartered in Long Beach, United States and has 357 employees. The company is worth $300.63M. Revenue was $181.98M in fiscal 2025, down 9.4% from the year before. It reported a net loss of $29.66M. The share price is 77.1% below its 52-week high of $13.93. One of the 38 superinvestors we track held it at the end of Q2 2026: Israel Englander (Millennium Management), at $4.49M. In that quarter, 1 of them opened or added to the position. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -25.3% over 5Y.
today you would have $680.17▼ -32.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 6 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $8.85 | $5.80 | $4.73 | $1.91 | $3.83 | $10.09 | |
| P/S | 2.3x | 4.0x | 2.2x | 2.1x | 1.4x | 2.4x | 4.4x |
| P/B | 3.8x | 9.8x | 3.8x | 3.8x | 0.7x | 0.8x | 8.2x |
| EPS | -$0.55 | -$0.21 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CGCCanopy Growth Corp | $0.67 | — | 0.6x | 0.00% | -39.51% | $298.92M |
| SMTISanara MedTech Inc. | $33.16 | — | 38.4x | 0.00% | -1.32% | $304.68M |
| ARCTArcturus Therapeutics Holdings Inc. | $10.73 | — | 1.8x | 0.00% | -46.31% | $304.98M |
| AGENAgenus Inc | $6.51 |
| -$1.62 |
| -$0.83 |
| -$1.11 |
| -$0.78 |
| Profit margin | -36.64% | -16.30% | 0.26% | -61.10% | -38.77% | -68.21% | -34.52% |
| ROE | -31.89% | -40.11% | 0.45% | -109.48% | -19.49% | -23.67% | -63.40% |
Median of the years shown; P/E years above 200x are left out.
| 2.6x |
| — |
| 0.00% |
| — |
| $294M |
| ARTVArtiva Biotherapeutics, Inc. | $5.85 | — | 0.8x | 0.00% | -36.58% | $286.01M |
| EBSEmergent BioSolutions Inc. | $6.23 | — | 0.9x | 0.00% | -40.29% | $319.43M |